Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Novartis has received a buy rating from JPMorgan for the first time in the CEO's tenure, marking a significant milestone for the company [2] - The company has focused on becoming a pure-play medicines company, divesting from non-core businesses to concentrate on high-end technologies in key therapeutic areas [2] Financial Performance - Novartis has reported strong sales and core operating income growth of 7% and 15% respectively [3] - The core operating margin is projected to reach 38.7% by 2024, with a goal of achieving 40% [3] - The company is on track to approach the 40% margin range in 2025, as indicated by performance in the third quarter [3]